The rate of exacerbations was reduced by @ % ( @ % confidence interval -LSB- CI -RSB- , @ to @ ) among patients receiving intravenous mepolizumab and by @ % ( @ % CI , @ to @ ) among those receiving subcutaneous mepolizumab , as compared with those receiving placebo ( P < @ for both comparisons ) .